Literature DB >> 19249518

Incidental hepatocellular carcinoma after liver transplantation: population characteristics and outcomes.

E Castillo1, S Pelletier, S Kumer, M Abouljoud, G Divine, D Moonka.   

Abstract

We combined data from two liver transplant centers to determine the tumor characteristics and outcomes of 51 patients transplanted with incidental hepatocellular carcinoma (iHCC) compared with 143 patients transplanted for previously known HCC (pkHCC). There were no differences in age, gender, or frequency of hepatitis C infection. Patients with iHCC were more likely to be African-American (22% vs 10%; P = .016), more likely to be screened by ultrasound (38% vs 9%; P < .001), had a lower alpha-fetoprotein (83.9 +/- 258.1 vs 572.4 +/- 2376.4 ng/mL; P = .005), and had a higher model for end-stage liver disease (MELD) score (14.3 +/- 4.1 vs 11.8 +/- 4.7; P < .001). The liver explants of patients with iHCC had smaller total tumor burden than patients with pkHCC (3.1 +/- 3.5 vs 4.1 +/- 2.6 cm; P < .001), but a similar percentage of single lesions (66% vs 65%) and tumors that met Milan criteria (76% vs 65%). Patients with iHCC had 1-, 3-, and 5-year survivals of 78%, 67%, and 58%, and 1-, 3-, and 5-year recurrence-free survivals of 90%, 87%, and 87% compared with the 1-, 3-, and 5-year survivals of 90%, 82%, and 70%, and the 1-, 3-, and 5-year tumor-free survivals of 91%, 84%, and 78% in patients with pkHCC. We concluded that patients with iHCC were more likely to be African-American, to be screened by ultrasound, to have a lower alpha-fetoprotein, and a higher MELD score. Ultrasound is not a sensitive modality for screening patients for HCC. Patients with iHCC do not have an advantage in survival over those with pkHCC.

Entities:  

Mesh:

Year:  2009        PMID: 19249518     DOI: 10.1016/j.transproceed.2008.10.053

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  6 in total

1.  Super-selection of a subgroup of hepatocellular carcinoma patients at minimal risk of recurrence for liver transplantation.

Authors:  Shin Hwang; Chul-Soo Ahn; Ki-Hun Kim; Deok-Bog Moon; Tae-Yong Ha; Gi-Won Song; Dong-Hwan Jung; Gil-Chun Park; Young-Dong Yu; Pyoung-Jae Park; Young-Il Choi; Kyoung-Won Kim; Young-Suk Lim; Han Chu Lee; Eun-Sil Yu; Sung-Gyu Lee
Journal:  J Gastrointest Surg       Date:  2011-03-29       Impact factor: 3.452

Review 2.  Computed tomography for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease.

Authors:  Tin Nadarevic; Vanja Giljaca; Agostino Colli; Mirella Fraquelli; Giovanni Casazza; Damir Miletic; Davor Štimac
Journal:  Cochrane Database Syst Rev       Date:  2021-10-06

Review 3.  Magnetic resonance imaging for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease.

Authors:  Tin Nadarevic; Agostino Colli; Vanja Giljaca; Mirella Fraquelli; Giovanni Casazza; Cristina Manzotti; Davor Štimac; Damir Miletic
Journal:  Cochrane Database Syst Rev       Date:  2022-05-06

4.  Incidence, Characteristics, and Prognosis of Incidentally Discovered Hepatocellular Carcinoma after Liver Transplantation.

Authors:  Walid El Moghazy; Samy Kashkoush; Glenda Meeberg; Norman Kneteman
Journal:  J Transplant       Date:  2016-06-15

5.  Incidental hepatocellular carcinoma after liver transplantation: Prevalence, histopathological features and prognostic impact.

Authors:  Pablo Pérez; Manuel Rodríguez-Perálvarez; Lourdes Guerrero; Víctor González; Rafael Sánchez; Macarena Centeno; Antonio Poyato; Javier Briceño; Marina Sánchez-Frías; Jose Luis Montero; Manuel De la Mata
Journal:  PLoS One       Date:  2017-04-12       Impact factor: 3.240

6.  Alpha-fetoprotein Level Predicts Recurrence After Transplantation in Hepatocellular Carcinoma.

Authors:  Luciana Dos Santos Schraiber; Angelo Alves de Mattos; Maria Lucia Zanotelli; Guido Pio Cracco Cantisani; Ajácio Bandeira de Mello Brandão; Cludio Augusto Marroni; Guilhermo Kiss; Lucas Ernani; Patrícia Dos Santos Marcon
Journal:  Medicine (Baltimore)       Date:  2016-01       Impact factor: 1.889

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.